Inhibitors of histone deacetylases (HDACs) are patent inducers of differentiation and bear considerable potential as drugs for chemoprevention and treatment of cancer. In this paper, we have investigated three synthetic, inhibitors A1a,b, A2a. Analogue hybrid trichostatine A (TSA), suberoylanilide hydroxamic acid SAHA, in order to seek new histone deacetylases (HDACs) inhibitors.
Introduction
H Hi is st to on ne e d de ea ac ce et ty yl la as se es s ( (H HD DA AC Cs s) ) a an nd d h hi is st to on ne e a ac ce et ty yl l transferases (HATs) are known to play an important role in the regulation of gene expression 1, 2 . HATs mediate hyperacetylation of positively charged lysine residues in the N-terminal tail of core histone and loosen the histone-DNA binding. As a result, activation of genes transcription can occur. In contrast HDACs catalyse deacetylation of the acetyl ε amino group residues and lead to the tight histone-DNA binding 3 . In this case, the access to transcription factors is restricted. These enzymes correlate with cell cycle progression, differentiation and apoptosis 4 and their deregulation is associated with tumorogenisis 5 .
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HDACs inhibitors have demonstrated potential for the prevention and treatment of cancer in numerous cell culture 6, 7 and animals models 8 . HDACs have emerged as an attractive target for new anticancer drugs and there is a great demand for new inhibitors 9, 10 .
The well known histone deacetylase inhibitor trichostatine A (TSA) 11, 12 (1), a natural product and other synthetic compounds such as suberoylanilide hydroxamic acid (SAHA) [13] [14] [15] (2) and analogues 16 , oxamflatin 17 (3), or MS-275 18 (4) possess potent antitumor effect in vivo in tumor-bearing animals 19 and some of them are currently in phase I or phase I / phase II clinical trials [20] [21] [22] [23] [24] ( Figure 1) . Figure 1 . Structures of known HDAC inhibitors These compounds consist of a hydrophobic scaffold with a spacer that is attached to a functional group which can interact with zinc ion present in the active site pocket [25] [26] . Compounds containing hydroxamic acid as a functional group are reported as the most potent inhibitors for HDACs 16 .
MS-275 (4)

Experimental
Nuclear magnetic resonance spectra ( 1 H NMR and 13 C NMR) were recorded on a Bruker 300 and 75 MHz. Flash column chromatography was performed using MACHEREY-NAGEL silica gel 60 (15-40 µm) as the stationary phase. All reactions were run under a positive pressure of nitrogen unless otherwise stated.
[1-(4-Methoxy-phenylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester (7a)
To a solution of N-(tert-butoxycarbonyl)-L-alanine 5 (32.5 mmol, 1 eq.) and aniline 6a (32.5 mmol, 1 eq.) in dimethylformamide (DMF) (80 mL) were added portion wise of diphenylphosphorylazide (DPPA) (7.7 mL, 33.7 mmol) and triethylamine (TEA) (9.70 mL, 69.8 mmol) at 0 °C. The stirring was continued at room temperature overnight. dimethylformamide was removed under reduced pressure. The residue was purified by flash chromatography (Ethyl acetate / Petroleum ether, 40/60) to give 7a (90%, white solid). 1 
2-Amino-N-(4-methoxy-phenyl)-propionamide (8a)
The protected compound 7a was dissolved in trifluoroacetic acid (TFA) (29 mL) at room temperature and kept for 2 h. The mixture was evaporated under reduced pressure. The residue was neutralised with Na 2 CO 3 and consecutively extracted with ethyl acetate. The organic layer was washed with water then brine, dried over Na 2 SO 4 
2-Amino-N-(4-dimethylamino-phenyl)-propionamide (8b)
White
4-[1-(4-Methoxy-phenylcarbamoyl)-ethylamino]-pent-4-enoic acid (9a)
To a solution of amine 8a in dimethylformamide (15 mL) were added succinic anhydride (8.81 mmol, 1 eq.) and triethylamine (1.23 mL, 8.81 mmol). The mixture was stirred for 4 h at room temperature. After evaporation of organic solvents, the residue was purified by flash chromatography using (CH 2 Cl 2 /MeOH , 90/10) to give compound 9a (93%, white solid). 
4-[1-(4-Dimethylamino-phenylcarbamoyl)-ethylamino]-pent-4-enoic acid (9b)
(
N-Hydroxy-N-[1-(4-methoxy-phenylcarbamoyl)-ethyl]-succinamide (A1-a)
To acid 9a (200 mg, 0.68 mmol), 1-[3(dimethylamino)propyl]-3-ethyl-carboimide hydrochloride] (EDC) (196.1 mg, 1.02 mmol), N-hydroxybenzotriazole (HOBT) (119.9 mg, 0.89 mmol) was reacted in dimethylformamide for 1 h. NH 2 OBn.HCl (108.9 mg, 0.68 mmol), triethylamine (0.10 mL, 0.68 mmol) were added and the mixture was stirred for 2 days. DMF was removed under reduced pressure. The residue was purified by flash chromatography using CH 2 The N-benzyl precursor (0.66 mmol) was dissolved in MeOH (10 mL), 10% Pd-C was added and the solution was shaken under H 2 . After 4h the mixture was filtered through celite and the filtrate was evaporated. The hydroxamic acid A1-a was isolated after purification of small sample on preparative plates (qt, withe solid). 1 
N-[1-(4-Dimethylamino-phenylcarbamoyl)-ethyl]-N`-hydroxy-succinamide (A1-b)
To a solution of acid 9b (0.5 mmol, 1 eq.) and NH 2 OBn.HCl (0.159 g, 1 eq.) in dimethylformamide (2 mL) diphenylphosphorylazide (0.12 mL, 0.55 mmol) and triethylamine (0.14 mL, 1 mmol) were added portion wise at 0 °C. The stirring was continued at room temperature for 1 h and 30 min. Dimethylformamide was removed under reduced pressure. The residue was purified by flash chromatography using CH 2 
4-Oxo-pent-2enoic acid [1-(4-methoxy-phenylcarbamoyl)-ethyl]-amide (10)
To a solution of mono ethyl ester fumaric acid (373 mg, 2,6 mmol) in DMF (7 mL) 1-[3(dimethylamino)propyl]-3-ethyl-carboimide hydrochloride (743.8 mg, 3.9 mmol) and Nhydroxybenzotriazole (455 mg, 3.37 mmol) were added. The mixture was stirred at room temperature for 1 h. Amine 8a (500 mg, 2.57 mmol) was added followed by triethylamine (0.36 mL, 2.57 mmoL). The mixture was stirred overnight, then the solvent was evaporated. The residue was purified by flash chromatography using EtOAc/EP, 50/50 to obtain compound 10 (white solid, 49%). 
But-2-enodioic acid hydroxyamide[1-(4-methoxy-phenylcarbamoyl)-ethyl]-amide (A2-a)
The ester 10 (130 mg, 0. 41 mmol) was dissolved in MeOH (40 mL) and an aqueous solution of LiOH (16.24 mL, 1 M) was added. The mixture was stirred for 2 h at the room temperature. The solution was neutralised with the amberlite resine IRN-77 then, the product was filtered and evaporated to give 3-[1-(4-methoxy-phenylcarbamoyl)-ethylcarbamoyl]-acrylic acid (white solid, 57%), which was used without further purification. 
Results and Discussion
As part of our efforts to search for novel HDACs inhibitors, we investigated a series of new hydroxamate analogues (A) which were designed as hybrides of TSA/SAHA (Figure 2) . Analogues hybrides TSA/SAHA The rationale for the structure relied on the following parameters. The presence of the amide function on the lateral chain instead of substituted alkene on the TSA, is one common feature shared by these analogues. We can then consider these analogues as TSA isosters. The presence of the carbonyl function on the lateral chain instead of the methyl one, introduces a new hydrophilic feature which can allow the formation of hydrogen binding in the tubular pocket of the enzyme. Such a modification could have an impact on the affinity toward HDACs. These analogues have an aryl recognition moiety which can be substituted in different ways. The orientation of the methyl in the chain is identical to that of TSA. The lateral chain comes from the acylation of an aromatic amine and leads to a pattern which is identical to that of SAHA. This chain will be saturated or unsaturated. In this paper we report the synthesis of these compounds. Scheme 1 shows a general synthetic route of the desired analogues A1-a,b and A2-a. The N-tert-butoxycarbonyl-L-alanine 5 was coupled with para substituted aniline 6a,b in several conditions. The use of N,N-bis(2-oxo-3-oxazolidinyl)-phosphinique chloride (BOP-Cl) as coupling reagent resulted in low yield 41%. Using DPPA to activate the carboxylic acid gave a 90% and 78% yield for respectively 7a and 7b. The N protecting group was removed after treatment with trifluoroacetic acid. The amine 8a,b reacted in DMF with succinic anhydride in the presence of TEA to give carboxylic acid 9a: 93%, and 9b: 61%. The resulting acid was converted to the O-benzyl protected hydroxamate. Subsequent catalytic hydrogenation of the protected group was used to generate the desired hydroxamates A1-a (qt), A1-b (73%).
The synthesis of the analogue A2-a started with the coupling of amine 8a with the monoethyl ester fumaric acid (Scheme 1). The ethyl ester 10 was cleaved under basic conditions in the presence of LiOH-MeOH and generated the corresponding acid with 57% yield. The acid was then converted to the O-THP (protected hydroxamate), using TBTU as coupling agent. The hydroxamic acid A2-a was isolated after purification of a small sample on the preparative plates with 66% yield. 
